MarketInOut Stock Screener Log In | Sign Up

Aclaris Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Aclaris Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization615.29 mln
Float111 mln
Earnings Date11/11/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

55.61
Highly suspicious

1-Year Forecast

10.09
Transformational upside

Relative Strength

97 / 100
Top performer

Debt / Equity

0.02
Debt-free

Pre-Tax Margin

-922%
Severely loss-making

Business Description

Aclaris Therapeutics is a US-based clinical-stage biopharmaceutical company focused on developing new treatments for immune and inflammatory diseases. Founded in 2012 and headquartered in Wayne, Pennsylvania, the company is advancing several drug candidates targeting conditions such as atopic dermatitis, asthma, chronic obstructive pulmonary disease, and other respiratory and autoimmune disorders. Its pipeline spans multiple stages of clinical testing, with therapies designed to work through a range of biological mechanisms that regulate immune cell activity.

Key Fundamentals

EPS-0.58
ROE-60.77
RPS0.06
ROIC-94.50
ROA-41.91
EBITDA, mln-75.22
EV / EBITDA-6.43
EV / EBIT-6.38
Revenue, mln8.22
EV / Revenue58.84

Quote Details

Last 3.97
Change -0.02 (-0.5%)
Open 4.00
Volume 1,880,364
Turnover 7,465,045
Average Volume 3,988,273

Financial Ratios

Pre-Tax Profit Margin-922
Leverage Ratio1.44
Current Ratio3.46
Price / Book4.25
Price / Tangible Book4.26
Debt / Equity0.02
Price / Sales59.22

Financial Strength

Altman Z-Score-2.67
Piotroski F-Score 4 / 9
Beneish M-Score55.61
1-Year Target Price10.09
Short Ratio3.86
Short % of Float11.59

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 5.87% 90 / 100   
1 Month -9.98% 29 / 100   
2 Months -26.07% 19 / 100   
6 Months -9.98% 36 / 100   
1 Year 69.66% 95 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog